File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Coriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer

TitleCoriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung cancer
Authors
KeywordsCoriolus versicolor
Lung cancer
Non-small cell lung cancer
Palliative treatment
Polysaccharide peptides (PSP)
Issue Date2003
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmed
Citation
Respiratory Medicine, 2003, v. 97 n. 6, p. 618-624 How to Cite?
AbstractBackground: Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths, and over 60% of patients present with advanced stages. Although polysaccharide peptides (PSP), isolated from the fungus Coriolus versicolor, have been reported to have anti-tumor effects, its clinical efficacy has not been properly evaluated. Methods: Double-blind placebo-controlled randomized study to evaluate the effects of 28-day administration of PSP (Windsor Pharmaceutical, Hong Kong) on patients, who had completed conventional treatment for advanced NSCLC. Results: Thirty-four patients, with no significant difference in their baseline demographic, clinical or tumor characteristics, or previous treatment regimes (P > 0.05), were recruited into each of the PSP and control arms. After 28-day treatment, there was a significant improvement in blood leukocyte and neutrophil counts, serum IgG and IgM, and percent of body fat among the PSP, but not the control, patients (P < 0.05). Although the evaluable PSP patients did not improve in NSCLC-related symptoms, there were significantly less PSP patients withdrawn due to disease progression, than their control counterparts (5.9 and 23.5%, respectively; P=0.04; OR 4.00). There was no reported adverse reaction attributable to the trial medications. Conclusion: PSP treatment appears to be associated with slower deterioration in patients with advanced NSCLC. © 2003 Elsevier Science Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/78320
ISSN
2015 Impact Factor: 3.036
2015 SCImago Journal Rankings: 1.396
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorTsang, KWen_HK
dc.contributor.authorLam, CLDen_HK
dc.contributor.authorYan, Cen_HK
dc.contributor.authorMak, JCen_HK
dc.contributor.authorOoi, GCen_HK
dc.contributor.authorHo, JCen_HK
dc.contributor.authorLam, Ben_HK
dc.contributor.authorMan, Ren_HK
dc.contributor.authorSham, JSen_HK
dc.contributor.authorLam, WKen_HK
dc.date.accessioned2010-09-06T07:41:35Z-
dc.date.available2010-09-06T07:41:35Z-
dc.date.issued2003en_HK
dc.identifier.citationRespiratory Medicine, 2003, v. 97 n. 6, p. 618-624en_HK
dc.identifier.issn0954-6111en_HK
dc.identifier.urihttp://hdl.handle.net/10722/78320-
dc.description.abstractBackground: Non-small cell lung cancer (NSCLC) is a leading cause of cancer deaths, and over 60% of patients present with advanced stages. Although polysaccharide peptides (PSP), isolated from the fungus Coriolus versicolor, have been reported to have anti-tumor effects, its clinical efficacy has not been properly evaluated. Methods: Double-blind placebo-controlled randomized study to evaluate the effects of 28-day administration of PSP (Windsor Pharmaceutical, Hong Kong) on patients, who had completed conventional treatment for advanced NSCLC. Results: Thirty-four patients, with no significant difference in their baseline demographic, clinical or tumor characteristics, or previous treatment regimes (P > 0.05), were recruited into each of the PSP and control arms. After 28-day treatment, there was a significant improvement in blood leukocyte and neutrophil counts, serum IgG and IgM, and percent of body fat among the PSP, but not the control, patients (P < 0.05). Although the evaluable PSP patients did not improve in NSCLC-related symptoms, there were significantly less PSP patients withdrawn due to disease progression, than their control counterparts (5.9 and 23.5%, respectively; P=0.04; OR 4.00). There was no reported adverse reaction attributable to the trial medications. Conclusion: PSP treatment appears to be associated with slower deterioration in patients with advanced NSCLC. © 2003 Elsevier Science Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/rmeden_HK
dc.relation.ispartofRespiratory Medicineen_HK
dc.subjectCoriolus versicoloren_HK
dc.subjectLung canceren_HK
dc.subjectNon-small cell lung canceren_HK
dc.subjectPalliative treatmenten_HK
dc.subjectPolysaccharide peptides (PSP)en_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAged, 80 and overen_HK
dc.subject.meshAntineoplastic Agents - therapeutic useen_HK
dc.subject.meshCarcinoma, Non-Small-Cell Lung - drug therapyen_HK
dc.subject.meshDisease Progressionen_HK
dc.subject.meshDouble-Blind Methoden_HK
dc.subject.meshFemaleen_HK
dc.subject.meshHumansen_HK
dc.subject.meshLung Neoplasms - drug therapyen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPilot Projectsen_HK
dc.subject.meshProteoglycans - therapeutic useen_HK
dc.titleCoriolus versicolor polysaccharide peptide slows progression of advanced non-small cell lung canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0954-6111&volume=97&spage=618&epage=624&date=2003&atitle=Coriolus+versicolor+polysaccharide+peptide+slows+progression+of+advanced+non-small+cell+lung+cancer+en_HK
dc.identifier.emailLam, CL: clklam@hku.hken_HK
dc.identifier.emailMak, JC: judymak@hku.hken_HK
dc.identifier.emailHo, JC: jhocm@hku.hken_HK
dc.identifier.emailMan, R: rykman@hkucc.hku.hken_HK
dc.identifier.authorityLam, CL=rp00350en_HK
dc.identifier.authorityMak, JC=rp00352en_HK
dc.identifier.authorityHo, JC=rp00258en_HK
dc.identifier.authorityMan, R=rp00236en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1053/rmed.2003.1490en_HK
dc.identifier.pmid12814145-
dc.identifier.scopuseid_2-s2.0-0037637485en_HK
dc.identifier.hkuros77989en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0037637485&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume97en_HK
dc.identifier.issue6en_HK
dc.identifier.spage618en_HK
dc.identifier.epage624en_HK
dc.identifier.isiWOS:000183387800005-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridTsang, KW=7201555024en_HK
dc.identifier.scopusauthoridLam, CL=24755913900en_HK
dc.identifier.scopusauthoridYan, C=8728540500en_HK
dc.identifier.scopusauthoridMak, JC=7103323094en_HK
dc.identifier.scopusauthoridOoi, GC=7006176119en_HK
dc.identifier.scopusauthoridHo, JC=7402649981en_HK
dc.identifier.scopusauthoridLam, B=9246012800en_HK
dc.identifier.scopusauthoridMan, R=7004986435en_HK
dc.identifier.scopusauthoridSham, JS=7101655565en_HK
dc.identifier.scopusauthoridLam, WK=7203021937en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats